TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05528926

Intervention type: OTHER
Group type: OTHER
Intervention: Non-Violent Resistance
Description: The program's core features are parental self-control and emotional support. In the NVR program, parents recruit supporters to help them deal with their children's problematic behaviours. Developing emotional control means that the parent opposes non-violent resistance to his child's behaviour, not escalating the explosive situation.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion).

Intervention type: OTHER
Group type: OTHER
Intervention: Parent Management Training
Description: The gold-standard treatment for disruptive behaviour disorder in children and adolescents. The objective is to train parents to cope with the difficult situations they encounter, to teach them effective control strategies that are coherent and adapted to the 'deviant' behaviour of their children to reduce the intensity of events and their repercussions within the family.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion).

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment As Usual
Description: The TAU group receives non-pharmacological and pharmacological therapies as usually provided in the participating centres but without having had a structured parent program in the last 6 months assessed at baseline, M1 and M3.
Study: NCT05379569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: The combination of fludarabine and cyclophosphamide has synergistic effect, which can better kill B lymphocyte, and can enhance the killing effect of pretreatment regimen on B lymphocyte tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: The combination of fludarabine and cyclophosphamide has synergistic effect, which can better kill B lymphocyte, and can enhance the killing effect of pretreatment regimen on B lymphocyte tumor.
Study: NCT05186350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP+ SpyGlass
Description: SpyGlass direct Vision guided laser lithotripsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESWL+ ERCP
Description: ESWL + Stone removal through ERCP
Study: NCT06321237

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus nerve stimulation for 8 weeks
Description: The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for 8 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation for the first 4 weeks
Description: The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for the first 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation for the last 4 weeks
Description: The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for the last 4 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pseudostimulus
Description: The patient is given some electrical stimulation but not vagus nerve stimulation
Study: NCT05951517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: MMF treat refractory gastrointestinal Henoch-Schönlein purpura
Study: NCT04695639

Intervention type: OTHER
Intervention: Test of Arm Selective Control
Description: It will be used to assess selective voluntary motor control. It is a reliable and valid evaluation tool used to quantify and describe selective voluntary motor control in children with spastic cerebral palsy. The goal of the assessment is to systematically evaluate a person's ability to move the upper extremity with selective voluntary motor control by observing movement control, coordination, fluency, mirroring, and speed at each joint, and then assigning a grade, all in 'real time. Clinically this measure may guide the selection of medical, surgical, or therapy interventions and may improve outcome prognosis after brief training. Raters demonstrated excellent reliability in assessing upper extremity SVMC in a group of children with hemiplegic, diplegic, and quadriplegic CP using the Ttest of arm selective control

Intervention type: OTHER
Intervention: Hand Held Dynamometer
Description: Hand held dynamometer (Camry Digital Hand Dynamometer Grip Strength, Model EH101-37, China) will be used to assess hand grip strength of the affected upper extremity. It is generally small, portable and relatively cheap reliable measurement instruments to measure muscle strength of the arm and hand in children with spastic cerebral pasly. It is used to measure strength; maximal voluntary isometric contraction; objectively in kilograms, pounds or newtons. Such devices have been proven to have good to excellent reliability in different populations. It represents an easily accessible way to assess muscle weakness in children with cerebral palsy and the overall reliability is considered to be good.

Intervention type: OTHER
Intervention: Quality of Upper Extremity Skill Test
Description: It will be used to assess function of the affected upper extremity. It is a reliable and valid outcome measure designed to evaluate movement patterns and hand function in children with cerebral palsy. It is designed to be used with children who have neuromotor dysfunction with spasticity and has been validated with children from 18 months to 8 years of age.
Study: NCT05485688

Intervention type: OTHER
Intervention: sleep apnea
Description: This prospective observational study will enroll 60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese \[BMI\>=27\] \& 30 non-obese \[BMI\<27\]) and 40 age-, gender-, BMI-matched controls without OSA. Venous blood 10 ml will be collected to isolate neutrophils, which are later tested for their ability to produce neutrophil extracellular traps (NETs) under the effect of PMA (phorbol 12-myristate 13-acetate).
Study: NCT05117086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: Nutrition education and counseling on DASH diet, behavioral and lifestyle modifications
Study: NCT05074563

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REsOluTioN (Resilience Enhancement Online Training for Nurses)
Description: The online REsOluTioN training involves virtual or face-to-face mentorship sessions and facilitated online interactive group sessions on four topics (Building hardiness and maintaining a positive outlook, Intellectual flexibility and Emotional Intelligence; Achieving life balance and enabling spirituality and Reflective and critical thinking). The training will be of four-week duration. Over the four-week period, the training will comprise 4x120 minute facilitated online group sessions; 4x30 minute independent learning activities; and eight 3:1 online mentoring sessions delivered between 30 and 60 minutes at flexible timings.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Nurses randomised to the control group will only be invited to take part in the pre- and post- intervention surveys, but will not use the online training. However, after completing the survey, nurses will be given the opportunity to complete the pre-work and access the facilitated sessions of the training so that they can receive their CPD certificate.
Study: NCT04563078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: 10-day treatment (2 per day with 10 minute break, 20 sessions in total) of active Transcranial Magnetic Stimulation (TMS). TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
Study: NCT06483750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Systane iLux Treatment
Description: The Systane iLux is an approved thermal pulsation device to treat dry eye disease. The application of heat and compression to both eyelids melts meibum in the obstructed glands to restore the secretion and production of meibum to the eye. The Systane iLux will only be administered to the eye to undergo cataract surgery.
Study: NCT03745664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Sodium Succinate
Description: During hospitalization, 40 mg of methylprednisolone (20 mg/ml) will be given intravenously twice a day (20 mg every 12 hours).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution for Injection
Description: During hospitalization, 2 ml of Saline Solution for Injection will be given intravenously twice a day (2 ml every 12 hours).
Study: NCT06507293

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block
Description: Before the general anesthesia induction, paravertebral block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spiane plane block
Description: Before the general anesthesia induction, erector spinae plane block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
Study: NCT05786924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDTX-4933
Description: RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDTX-4933
Description: RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations
Study: NCT06393452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PP405 0.05% Topical Gel
Description: PP405 is an inhibitor of mitochondrial pyruvate carrier (MPC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PP405 Topical Vehicle Gel
Description: PP405 Vehicle = placebo
Study: NCT05202561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNA tumor vaccine
Description: Subjects will receive single dose of RNA tumor vaccine injection on day 1, day 4, day 7, and day 14, each dose of 600 ng.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNA tumor vaccine+Navuliumab
Description: RNA tumor vaccine+Navuliumab Subjects will receive maintenance therapy with a PD-1 inhibitor in addition to monotherapy with the RNA tumor vaccine injection. Subjects received a single dose of RNA vaccine injection on day 1, day 4, day 7, and day 14, with each dose of 600 ng. Inhibitors, accept the Navuliumab on day 14, the recommended dose is 3 mg/kg, intravenous injection every 2 weeks.
Study: NCT06670040

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: All TBS sessions will be delivered at the same site, intensity (up to 90% RMT), pattern and duration. Treatment conditions differ only in the amount of intracranial activation induced (i.e., negligible activation in sham condition). TBS sessions consist of triplet 50 Hz bursts repeated every 200 msec (5 Hz), delivered to the left DLPFC in an intermittent (2 seconds on/8 seconds off) pattern for a total of 600 pulses per session; duration of 3 minutes 9 seconds.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Sham
Description: We will use a robust sham technique that suitably replicates the sensory experience (auditory and peripheral activation) of active TBS with minimal intracranial activation. The Magstim Horizon™ sham coil will be utilized for treatment delivery. This sham coil is visually identical to the active coil and replicates the sounds and sensation of the magnetic stimulation. All sham treatment will be delivered at the same site, intensity (up to 90% RMT), pattern and duration. Treatment conditions differ only in the amount of intracranial activation induced (i.e., negligible activation in sham condition). TBS sessions consist of triplet 50 Hz bursts repeated every 200 msec (5 Hz), delivered to the left DLPFC in an intermittent (2 seconds on/8 seconds off) pattern for a total of 600 pulses per session; duration of 3 minutes 9 seconds
Study: NCT06670547

Intervention type: PROCEDURE
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Description: Endoscopic retrograde cholangiopancreatography (ERCP)
Study: NCT06669390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG11-2
Description: NG11-2 dose level will vary from 0.92 mg/mL to 5.5 mg/mL during the dose escalation process. The NG11-2 is given as an oral rinse.~Throughout the radiotherapy regimen, no more than 60 minutes prior to the completion of radiotherapy, on each weekday the patient will rinse their mouth with 12.5 ml of NG11-2 for between 90 \& 120 seconds duration, gargling twice for approximately three seconds each if possible during this period then expectorate the solution.
Study: NCT06669897

Intervention type: OTHER
Intervention: Questionnaire
Description: Chronic cough questionnaire
Study: NCT06669598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Electromyostimulation
Description: The ETG group underwent in two 20-minute training sessions per week (12 weeks), with 72 hours of rest between sessions. Each session included aerobic activities such as rowing and treadmill exercises, combined with supervised WB-EMS stimulation. This stimu-lation utilised a rectangular waveform at 35 Hz, 350 μs, with continuous pulse dura-tion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The CON group underwent three weekly training sessions for twelve weeks, con-sisting of 20 minutes of aerobic activity, performed on a treadmill and rowing machine, without the WB-EMS superimposition.
Study: NCT06538090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Movers
Description: The intervention includes: 1) an educational resource (i.e., hard-copy handout) developed for this study on the 24-Hour Movement Guidelines provided to parents at 2-month immunization appointments by public health nurses, who will answer any questions, followed by a discussion with research staff. 2) Follow-up support via access to a digital app with evidence-based information and support through an online toolkit, an anonymous forum, as well as weekly text messages that include tips and supportive messaging related to the guidelines.
Study: NCT06670352

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD or BID, 24-weeks fixed dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297 50mgBID
Description: 24-weeks fixed dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297 100mgBID
Description: 24-weeks fixed dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297 200mgQD
Description: 24-weeks fixed dose.
Study: NCT06668974

Intervention type: OTHER
Intervention: Mendelian Randomization
Description: This study utilizes a bidirectional Mendelian randomization approach to analyze genetic data from individuals with allergic rhinitis and asthma. No active intervention is applied; genetic variants serve as instrumental variables to assess causal associations between the conditions.

Intervention type: OTHER
Intervention: Mendelian Randomization
Description: This study utilizes a bidirectional Mendelian randomization approach to analyze genetic data from individuals with allergic rhinitis and asthma. No active intervention is applied; genetic variants serve as instrumental variables to assess causal associations between the conditions.
Study: NCT06670274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC002 SAD
Description: Part 1 will enroll 40 participants across 5 cohorts.~Route of administration: Oral Dose interval and frequency: Single oral dose range across 5 cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC002 MAD
Description: Part 2 will enroll 24 participants across 3 cohorts.~Route of administration: Oral Dose interval and frequency: Once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered across SAD and MAD
Study: NCT06669975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP402 (Part 1 Dose esclation)
Description: Dose escalation will consist of 7 cohorts where an Intraveous infusion of AP402 will be administered once every 2 weeks to determine the maximum tolerated dose (MTD) (ie, the highest safe dose administered to patients) and the recommended phase 2 dose (RP2D) of AP402.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP402 (Part 2 Dose Expansion)
Description: After the MTD and/or RP2D are determined by the SRC, additional patients will be enrolled in Phase 2 dose expansion and will be treated with AP402 at that dose.
Study: NCT04348604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA)
Description: Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA): CAE-AYA participants will have 4 core in-person sessions (45-60 minutes each) spaced about 1 week apart over a period of approximately 4 weeks and one booster in-person session approximately 4 weeks after completion of the 4 core sessions (total of up to 5 in-person sessions spaced out over 8 weeks). There will be one follow-up phone call with a study interventionist, approximately 6 weeks post-baseline (timed half-way between completion of the core sessions and the booster session). All AYAs assigned to the CAE-AYA arm will receive all 4 modules (Psychoeducation on BD Medications; Communication with Providers \& Caregivers; Medication Routines; and Targeting Risky Behavior via Modified Motivational Enhancement Therapy (MET)), with the content within each module being customized to developmental stage and behavioral experience.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Description: Enhanced Treatment as Usual (ETAU): ETAU will consist of usual clinical care with prescribing clinicians and therapists, augmented by written materials specific to BD for AYAs and 6 follow-up telephone calls to briefly review the materials and be available for questions by social workers with mental health experience and at least some experience in working with AYA with BD. In order to ensure that there is not treatment contamination, different trained interventionists will be used for CAE and eTAU. Therapists will briefly review the materials and be available for questions during the phone calls. Materials will cover general self-management in BD. The calls will be relatively brief (maximum of 20-30 minutes).
Study: NCT06670690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol 50 MG
Description: patients will be premedicated with atenolol (50mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol Pill
Description: patients will be premedicated with propranolol (10mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: patients will be premedicated with Ivabradine (5mg)
Study: NCT06668987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B10 L-BPA Injection
Description: The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.
Study: NCT05245864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood flow restriction
Description: Blood flow to the legs will be mostly restricted temporarily during physical therapy exercises for the initial several weeks of physical therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: physical therapy standard of care
Description: the current standard of care after surgery for ACL repair.
Study: NCT06293235

Intervention type: OTHER
Intervention: Lifestyle and metabolic indicators
Description: Socio-demographics, health history, behavioural characteristics, environmental exposures, anthropometric measurements, body fat composition, metabolic and stress biomarkers, semen physical and molecular characteristics.

Intervention type: OTHER
Intervention: Lifestyle and metabolic indicators
Description: Socio-demographics, health history, behavioural characteristics, environmental exposures, anthropometric measurements, body fat composition, metabolic and stress biomarkers, semen physical and molecular characteristics.
Study: NCT04563078

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation (TMS)
Description: 10-day treatment (2 per day with 10 minute break, 20 sessions in total) of sham control.
Study: NCT05772234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated ringers solution
Description: Intravenous 20 mL/kg Ringer's lactate solution within 60 min from the start of ESWL, directly followed by 3 mL/kg per h for 8 h.
Study: NCT04928235

Intervention type: DIAGNOSTIC_TEST
Intervention: Thermal Imaging as Diagnostic Adjunct
Description: Thermal images of the participants lower extremities will be taken and skin surface temperature values will be provided to the healthcare provider for review during the emergency department encounter.
Study: NCT05772234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: Intravenous fluid infusion with normal saline (maximum of 1.5mL/kg per h or 3L per 24h).
Study: NCT05522517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosentyx
Description: Cosentyx injection will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candin
Description: Candin will be administered interadermally along with NaCl solution.
Study: NCT05277922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C21
Description: C21 in ascending doses of 15, 50, 150, 500 and 1000 µg
Study: NCT06628206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPX-TI641
Description: Oral solution administered QD for 28 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPX-TI641
Description: Oral solution administered QD for 28 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Drug is LPX-TI641 oral solution. Placebo an identical oral solution without the LPX-TI641.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Drug is LPX-TI641 oral solution. Placebo an identical oral solution without the LPX-TI641.
Study: NCT06630871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Distitamab Vedotin in combination with Tislelizumab
Description: On the day after the initial TURBt procedure, use trastuzumab (200mg)+ Distitamab Vedotin (120mg \[≤ 60Kg\] or 2.0mg/Kg \[\>60Kg\]) every 3 weeks (Q3W). Simultaneously arrange for the patient to complete a second TURBt within 6 weeks, and continue to use 3 courses of Trastuzumab+Vediximab (Q3W) after surgery until the endpoint of 3-year follow-up
Study: NCT06633640

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional flap with algae-based substitute (AlgOss) combined with collagen membrane.
Description: The graft material will be prepared following the manufacturer instruction, transferred into a sterile cup than the mixture is condensed without overfilling in the intrabony defect to the level of the surrounding bony walls. The filled site will be than covered with collagen membrane.